SARASOTA, Fla., July 7, 2026
Lakewood-Amedex Biotherapeutics has announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, reaffirming its commitment to advancing innovative antimicrobial therapies to combat the escalating global threat of antimicrobial resistance (AMR). The clinical-stage biotechnology company believes the proposed legislation will strengthen incentives for the development of novel anti-infective medicines capable of addressing drug-resistant bacterial infections that continue to challenge healthcare systems worldwide. Alongside its support for the legislation, the company highlighted the potential of its proprietary Bisphosphocin® antimicrobial platform and its lead investigational therapy Nu-3, which is preparing to enter Phase 2 clinical development for the treatment of infected diabetic foot ulcers (iDFUs). With antibiotic resistance recognized as one of the most urgent global public health threats, Lakewood-Amedex believes innovative technologies combined with supportive policy initiatives are essential to accelerating the development of next-generation antimicrobial therapies and improving patient outcomes.
Bisphosphocin® Platform Targets Drug-Resistant Bacterial Infections
At the center of Lakewood-Amedex’s innovation strategy is its proprietary Bisphosphocin® class of antimicrobials, a novel platform designed to rapidly eliminate bacteria through pH- and concentration-dependent destabilization of bacterial cell membranes. Unlike conventional antibiotics, this differentiated mechanism of action has demonstrated strong in vitro activity against several clinically important antibiotic-resistant pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE). Early laboratory findings also suggest the platform may reduce the likelihood of resistance development compared with traditional antimicrobial therapies, addressing one of the most significant challenges facing infectious disease treatment today.
According to Dr. Kelvin Cooper, Chief Executive Officer of Lakewood-Amedex Biotherapeutics, the reintroduction of the PASTEUR Act recognizes the urgent need for continued innovation in antimicrobial drug development and reinforces the importance of advancing differentiated therapeutic platforms capable of combating resistant microbial infections.
Nu-3 Advances Toward Phase 2 for Infected Diabetic Foot Ulcers
Advertisement
Lakewood-Amedex is preparing to initiate Phase 2 clinical development for Nu-3, its lead topical antimicrobial candidate being developed for the treatment of infected diabetic foot ulcers (iDFUs). These infections affect millions of patients worldwide and remain a leading cause of hospitalization, prolonged wound complications, and lower-limb amputations among individuals with diabetes. The increasing prevalence of antibiotic-resistant bacteria has further complicated treatment, creating a substantial unmet medical need for innovative therapies capable of rapidly controlling infection while reducing the emergence of resistance. The company’s clinical development strategy aligns closely with the objectives of the PASTEUR Act, which seeks to establish sustainable incentives encouraging pharmaceutical companies to invest in novel antimicrobial research and development.
By combining policy support, innovative antimicrobial science, and clinical-stage therapeutic development, Lakewood-Amedex aims to contribute to the global effort to address the growing burden of antimicrobial resistance. As healthcare organizations and governments continue prioritizing solutions to combat resistant infections, the company’s Bisphosphocin® platform and Nu-3 clinical program represent promising advances that could help reshape the future of infectious disease treatment while supporting responsible antimicrobial stewardship and improving outcomes for patients facing difficult-to-treat bacterial infections.
Source: Lakewood-Amedex Biotherapeutics press release
